MAPT and Alzheimer disease: However, during the progression of AD, increases in CSF p-tau217 (tau phosphorylated at threonine 217) are significantly higher than CSF p-tau181, suggesting a better performance of CSF p-tau217 in the diagnosis of early and advanced stages of AD [131].